Evaluating imaging techniques for detecting recurrent ovarian cancer
Official title: Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy
Run by Chang Gung Memorial Hospital · NCT06232122 · Data updated 2026-11-12
This study is testing two different imaging methods to see which one is better at finding recurring ovarian cancer in patients whose CA125 levels have gone up after treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 80 Years |
| Sex | Women only |
| Enrollment | 45 (estimated) |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Taoyuan City) |
| Status | Recruiting |
| Started | August 1, 2022 |
| Main results expected | July 31, 2028 |
| Study ends | July 31, 2028 |
| Registry record updated | January 30, 2024 |
| Trial ID | NCT06232122 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women aged 30 to 80 with pathologically proven ovarian cancer who have achieved a complete response after therapy and have elevated CA125 levels.
✕Probably not a fit
Patients with a history of other malignancies, those who are pregnant or lactating, or individuals unable to undergo the required imaging procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the effectiveness of two imaging techniques, 68Ga-FAPI-46 and 18F-FDG PET/CT, in detecting recurrent tumor lesions in patients with ovarian cancer who have shown an elevation in CA125 levels after achieving a complete response to therapy. The research will involve a prospective cohort of patients at a single institution, focusing on those whose CA125 levels indicate potential recurrence. By comparing the diagnostic performances of both imaging methods, the study seeks to improve management strategies for ovarian cancer patients.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection of recurrent ovarian cancer, allowing for timely intervention and improved patient outcomes.
How similar studies have gone: Previous studies have shown that 18F-FDG PET/CT can modify management in a significant number of patients, indicating that this approach has potential, though the use of 68Ga-FAPI-46 is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically proven ovarian cancer with complete response after therapy * Age between 30 and 80 * Elevation of serum CA125 value above the normal range (\>35 U/mL) or doubling of serum CA125 value within the normal range * ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed * Willing to enter this prospective study with signed informed consent form Exclusion Criteria: * Patients with history of other malignancy * Patients who are pregnant or lactating * Patients with fasting fingerstick glucose level higher than 200 mg/dl * Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies * Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators
Where it's running
-
Chang-Gung Memorial Hospital, Linkou Branch
Taoyuan City, Taiwan Recruiting
Study contacts
- Study coordinator: Feng-Yuan Liu
- Email: billliu@cgmh.org.tw
- Phone: 0975365782
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.